{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:05:18Z","timestamp":1788051918597,"version":"build-2784847793"},"reference-count":48,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:00:00Z","timestamp":1526428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>BFE1224, prodrug of ravuconazole, is a novel, once\u2010daily, oral, triazole antifungal drug, and currently in development for the treatment of onychomycosis. The clinical drug\u2013drug interaction (DDI) potential of BFE1224 with cytochrome P450 (CYP) and transporter was assessed by using two types of cocktails in healthy subjects in separate clinical studies. The CYP and transporter cocktails consisted of caffeine\/tolbutamide\/omeprazole\/dextromethorphan\/midazolam used in study 1 and digoxin\/rosuvastatin used in study 2. In addition, repaglinide was separately administered to the same subjects in study 2. There were no major effects on the pharmacokinetics of CYP and transporter substrates, except for an approximate threefold increase in midazolam exposure after oral administration of BFE1224. The clinical DDIs of BFE1224 were mild for CYP3A and minor for other major CYPs (CYP1A2\/2C8\/2C9\/2C19\/2D6) as well as those of P\u2010glycoprotein (P\u2010gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, and OATP1B3.<\/jats:p>","DOI":"10.1111\/cts.12557","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T14:48:26Z","timestamp":1526482106000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical Drug\u2013Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects"],"prefix":"10.1111","volume":"11","author":[{"given":"Yasuyuki","family":"Ishii","sequence":"first","affiliation":[{"name":"Shinagawa R&amp;D Center Sato Pharmaceutical Co. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ito","sequence":"additional","affiliation":[{"name":"Shinagawa R&amp;D Center Sato Pharmaceutical Co. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Clinical Research Center Souseikai Fukuoka Mirai Hospital Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasumi","family":"Sanpei","sequence":"additional","affiliation":[{"name":"Clinical Research Department Sato Pharmaceutical Co. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Research and Development Seren Pharmaceuticals Inc. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Takeda","sequence":"additional","affiliation":[{"name":"Research and Development Seren Pharmaceuticals Inc. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar L.","family":"Schuck","sequence":"additional","affiliation":[{"name":"Medicines Development Center Eisai Inc. Woodcliff Lake New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Faculty of Medicine Oita University Oita Japan"},{"name":"Clinical Pharmacology Center Oita University Hospital Oita Japan"},{"name":"General Clinical Research Center (GCRC) Oita University Hospital Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"key":"e_1_2_8_1_1","doi-asserted-by":"publisher","DOI":"10.3314\/mmj.16-00006"},{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3314\/mmj.57.J71"},{"key":"e_1_2_8_3_1","volume-title":"Lamisil (package insert)","year":"2013"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0090-9556(24)15022-2","article-title":"Multiple cytochrome P\u2010450s involved in the metabolism of terbinafine suggest a limited potential for drug\u2010drug interactions","volume":"27","author":"Vickers A.E","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0090-9556(24)15224-5","article-title":"Potent inhibition of cytochrome P\u2010450 2D6\u2010mediated dextromethorphan O\u2010demethylation by terbinafine","volume":"27","author":"Abdel\u2010Rahman S.M","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127002762491299"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.3.492"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70065-2"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0217-9"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1067-2516(99)80072-6"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80215-0"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.000315"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/598327"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90165-5"},{"key":"e_1_2_8_15_1","unstructured":"Sporanox capsules (package insert).Titusville NJ:Janssen Pharmaceuticals(2012)."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1996.tb00273.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199712000-00001"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2237"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.313"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1723-1727.2002"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1032-1037.2002"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780410001731583"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780701549364"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3314\/mmj.55.J157"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01212.x"},{"key":"e_1_2_8_26_1","unstructured":"PMDA.Drug interaction guideline for drug development and labeling recommendations. (2014)."},{"key":"e_1_2_8_27_1","unstructured":"FDA.Guidance for industry. Drug interaction studies: study design data analysis implications for dosing and labeling recommendations. (2006)."},{"key":"e_1_2_8_28_1","unstructured":"EMA.Guideline on the investigation of drug interactions. (2012)."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.109519"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00229-7"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0115-0"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100187"},{"key":"e_1_2_8_33_1","volume-title":"Surepost (interview form)","year":"2017"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01973.x"},{"key":"e_1_2_8_35_1","first-page":"1023","article-title":"In vivo effect of clarithromycin on multiple cytochrome P450s","volume":"29","author":"Bruce M.A.","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1995.tb05740.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.406"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270002042012008"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.01.035"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.034629"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-11-RV-098"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005283462"},{"key":"e_1_2_8_43_1","unstructured":"Mummaneni V.et\u00a0al.Effect of ravuconazole on the pharmacokinetics of simvastatin in healthy subjects. In abstracts of the 40thInterscience Conference on Antimicrobial Agents and Chemotherapy Toronto Canada A\u201084.1 p. 23(2000)."},{"key":"e_1_2_8_44_1","first-page":"299","article-title":"Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality","volume":"1","author":"Elewski B.","year":"2005","journal-title":"Ther. Clin. Risk Manag."},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.184"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.60"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90191-0"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010365885"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcts.12557","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T11:39:04Z","timestamp":1751629144000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/cts.12557"],"URL":"https:\/\/doi.org\/10.1111\/cts.12557","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,16]]},"assertion":[{"value":"2017-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}